Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

AARP

NJTV News: Specialty Drugs Cost More Than Most Yearly Incomes; HINJ CEO Interviewed

NJTV News w Mary Alice WilliamsNewark, NJ, December 7, 2015 ― In a segment broadcast on December 4, NJTV News correspondent Erin Delmore explored prescription drug prices in the US. and consumer concerns.

Assemblyman Daniel Benson (D-14), Vice Chair of the Health & Senior Services Committee, says mounting drug prices — including Turing Pharmaceuticals’ hiking a lifesaving medication by 5,000 percent — have prompted concerned New Jerseyans to call his office, even if they have insurance.

“What we’re hearing, for the most part is: ‘I’ve bought insurance, I’m paying these large premiums per month and I still can’t get the drugs that I need to have a quality, a frame of life, because the co-pays are so high,’” Benson told Delmore. Continue reading

New AARP Report Finds Generic Drug Prices Dropping More Slowly

Washington, DC, May 28, 2015 ― The new Rx Price Watch Report released today by AARP Public Policy Institute (PPI) shows a number of popular generic drugs had substantial price increases, with some prices going up as much as 1,000 percent.  Overall, retail prices for generic prescription drugs widely used by older Americans fell an average of 4 percent in 2013.

Although generic drug prices have been consistently declining over the past several years, the latest annual data available showed the smallest average annual decline since at least 2006, a sign that the era of falling prices for generic drugs could be coming to an end. Continue reading